Patient and disease characteristics and length of follow-up in randomized autograft versus chemotherapy trials
| Trial . | N . | Sex . | Age, y . | WBC . | Immunophenotype . | Ph+ . | Median follow-up, y . | Lost to follow-up < 5 y . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M . | F . | < 25 . | 25-34 . | 35-44 . | ≥ 45 . | < 30 . | 30-99 . | ≥ 100 . | B . | T . | Other . | Yes . | No . | ||||
| EORTC ALL-3/0686111 | 45 | 32 (71%) | 13 (29%) | 16 (36%) | 13 (29%) | 10 (22%) | 6 (13%) | 26 (58%) | 10 (22%) | 9 (20%) | 26 (65%) | 9 (23%) | 5 (13%) | 2 (10%) | 18 (90%) | 9.4 | 2 (4%) |
| UKALLXII/E299314 | 457 | 284 (62%) | 173 (38%) | 159 (35%) | 110 (24%) | 89 (19%) | 99 (22%) | 320 (70%) | 84 (19%) | 50 (11%) | 333 (76%) | 99 (23%) | 6 (1%) | 16 (4%) | 385 (96%) | 8.4 | 34 (7%) |
| PETHEMA ALL-9315 | 98 | 57 (58%) | 41 (42%) | 46 (47%) | 26 (27%) | 17 (17%) | 9 (9%) | 58 (59%) | 21 (21%) | 19 (19%) | 69 (70%) | 29 (30%) | 0 (0%) | 14 (15%) | 78 (85%) | 5.6 | 18 (18%) |
| LALA-9416 | 152 | 101 (66%) | 51 (34%) | 56 (37%) | 25 (16%) | 35 (23%) | 36 (24%) | 89 (59%) | 34 (22%) | 29 (19%) | 103 (79%) | 26 (20%) | 1 (1%) | 0 (0%) | 107 (100%) | 6.2 | 16 (11%) |
| EORTC ALL-4/0695117 | 77 | 47 (61%) | 30 (39%) | 33 (43%) | 15 (19%) | 14 (18%) | 15 (19%) | 49 (64%) | 16 (21%) | 12 (16%) | 39 (51%) | 33 (43%) | 5 (6%) | 0 (0%) | 40 (100%) | 7.2 | 9 (12%) |
| Autograft | 429 | 269 (63%) | 160 (37%) | 159 (37%) | 108 (25%) | 80 (19%) | 82 (19%) | 277 (65%) | 87 (20%) | 64 (15%) | 282 (69%) | 115 (28%) | 10 (2%) | 17 (5%) | 329 (95%) | 7.7 | 37 (9%) |
| Chemotherapy | 400 | 252 (63%) | 148 (37%) | 151 (38%) | 81 (20%) | 85 (21%) | 83 (21%) | 265 (67%) | 78 (20%) | 55 (14%) | 288 (77%) | 81 (21%) | 7 (2%) | 15 (5%) | 299 (95%) | 7.6 | 42 (10%) |
| Trial . | N . | Sex . | Age, y . | WBC . | Immunophenotype . | Ph+ . | Median follow-up, y . | Lost to follow-up < 5 y . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M . | F . | < 25 . | 25-34 . | 35-44 . | ≥ 45 . | < 30 . | 30-99 . | ≥ 100 . | B . | T . | Other . | Yes . | No . | ||||
| EORTC ALL-3/0686111 | 45 | 32 (71%) | 13 (29%) | 16 (36%) | 13 (29%) | 10 (22%) | 6 (13%) | 26 (58%) | 10 (22%) | 9 (20%) | 26 (65%) | 9 (23%) | 5 (13%) | 2 (10%) | 18 (90%) | 9.4 | 2 (4%) |
| UKALLXII/E299314 | 457 | 284 (62%) | 173 (38%) | 159 (35%) | 110 (24%) | 89 (19%) | 99 (22%) | 320 (70%) | 84 (19%) | 50 (11%) | 333 (76%) | 99 (23%) | 6 (1%) | 16 (4%) | 385 (96%) | 8.4 | 34 (7%) |
| PETHEMA ALL-9315 | 98 | 57 (58%) | 41 (42%) | 46 (47%) | 26 (27%) | 17 (17%) | 9 (9%) | 58 (59%) | 21 (21%) | 19 (19%) | 69 (70%) | 29 (30%) | 0 (0%) | 14 (15%) | 78 (85%) | 5.6 | 18 (18%) |
| LALA-9416 | 152 | 101 (66%) | 51 (34%) | 56 (37%) | 25 (16%) | 35 (23%) | 36 (24%) | 89 (59%) | 34 (22%) | 29 (19%) | 103 (79%) | 26 (20%) | 1 (1%) | 0 (0%) | 107 (100%) | 6.2 | 16 (11%) |
| EORTC ALL-4/0695117 | 77 | 47 (61%) | 30 (39%) | 33 (43%) | 15 (19%) | 14 (18%) | 15 (19%) | 49 (64%) | 16 (21%) | 12 (16%) | 39 (51%) | 33 (43%) | 5 (6%) | 0 (0%) | 40 (100%) | 7.2 | 9 (12%) |
| Autograft | 429 | 269 (63%) | 160 (37%) | 159 (37%) | 108 (25%) | 80 (19%) | 82 (19%) | 277 (65%) | 87 (20%) | 64 (15%) | 282 (69%) | 115 (28%) | 10 (2%) | 17 (5%) | 329 (95%) | 7.7 | 37 (9%) |
| Chemotherapy | 400 | 252 (63%) | 148 (37%) | 151 (38%) | 81 (20%) | 85 (21%) | 83 (21%) | 265 (67%) | 78 (20%) | 55 (14%) | 288 (77%) | 81 (21%) | 7 (2%) | 15 (5%) | 299 (95%) | 7.6 | 42 (10%) |